Welcome to chemicalbook!
Chinese English Japanese Germany Korea
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook CAS DataBase List Regorafenib

Regorafenib synthesis

12synthesis methods
Regorafenib, also known as BAY 73-4506 ; is an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. Regorafenib demonstrated to increase the overall survival of patients with metastatic colorectal cancer
Synthetic Routes
  • ROUTE 1
  • 202112071911984119.jpg

    Du, Fangyu; Zhou, Qifan; Shi, Yajie; Yu, Miao; Sun, Wenjiao; Chen, Guoliang. A new pathway via intermediate 4-​amino-​3-​fluorophenol for the synthesis of regorafenib. Synthetic Communications. Volume 49. Issue 4. Pages 576-586. Journal; Online Computer File. (2019).

  • ROUTE 2
  • 202112075680659178.jpg

    Research on Chemical Intermediates Volume 42 Issue 4 Pages 3209-3218 Journal; Online Computer File 2016

  • ROUTE 3
  • 202112076683199905.jpg

    Liu, Zhenteng; Liu, Xinquan; Wei, Shuhong; Gao, Ruizhao. Method for preparing regorafenib. Assignee Shandong Luoxin Pharmaceutical Group Hengxin Pharmaceutical Co., Ltd., Peop. Rep. China. CN 108558747. (2018).

  • ROUTE 4
  • 202112074927738616.jpg

    : Oruganti, Srinivas; Rapolu, Rajesh Kumar. Processes for the preparation of diphenyl urea derivatives and novel intermediates thereof. Assignee Dr. Reddy's Laboratories Limited, India. IN 2014CH01136. (2016).

  • ROUTE 5
  • 202112071212283730.jpg

    Sun, Song; Li, Qiang; Hou, Xiaolong. Preparation method of Regorafenib. Assignee Shandong Luoxin Pharmaceutical Group Co., Ltd., Peop. Rep. China. CN 105330600. (2016).

  • ROUTE 6
  • 202112070819449332.jpg

    Xu, Qiang; Huang, Shuang; Yang, Jian; Wang, Ping; Xia, Bin; Qian, Gang. Process for the preparation of regorafenib. Assignee Jiangsu Zhongbang Pharmaceutical Co., Ltd., Peop. Rep. China. CN 105130887. (2015).

202112071911984119.jpg

Du, Fangyu; Zhou, Qifan; Shi, Yajie; Yu, Miao; Sun, Wenjiao; Chen, Guoliang. A new pathway via intermediate 4-​amino-​3-​fluorophenol for the synthesis of regorafenib. Synthetic Communications. Volume 49. Issue 4. Pages 576-586. Journal; Online Computer File. (2019).

757251-39-1 Synthesis
4-(4-AMINO-3-FLUOROPHENOXY)-N-METHYLPICOLINAMIDE

757251-39-1
234 suppliers
$11.00/250mg

42558-54-3 Synthesis
Methyl isobutyrylacetate

42558-54-3
382 suppliers
$10.00/5g

-

Yield:755037-03-7 96.8%

Reaction Conditions:

with dmap in N,N-dimethyl-formamide at 140; for 4 h;Green chemistry;Temperature;

Steps:

8 Preparation of regomafenib (I)
To the reaction flask, a compound IV 13.27 g, a compound V 9.93 g, a methyl isobutyryl acetate 7.32 g, a 4-dimethylaminopyridine 6.21 g, and 800 ml of DMF were sequentially added, and the mixture was stirred and dissolved, and the temperature was controlled at 140 ° C for 4 h. The TLC monitors the completion of the reaction. The reaction was stopped, the temperature was lowered to room temperature, and ethyl acetate was added for extraction. The organic layer was separated and concentrated under reduced pressure to give 25.55 g, product yield 96.8%, purity 99.93%.

References:

Shandong Luoxin Pharmaceutical Group Hengxin Pharmaceutical Co., Ltd.;Liu Zhenteng;Hou Junkai;Fan Xuezhen;Yang Taotao CN108329260, 2018, A Location in patent:Paragraph 0014; 0037; 0040; 0043-0046

FullText

Regorafenib Related Search: